DRICLOR

Main information

  • Trade name:
  • DRICLOR Cutaneous Powder 0.20 %w/ w
  • Dosage:
  • 0.20 %w/ w
  • Pharmaceutical form:
  • Cutaneous Powder
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • DRICLOR Cutaneous Powder 0.20 %w/w
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0144/012/002
  • Authorization date:
  • 01-10-1984
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

DriclorPowder

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Aldioxa0.20%w/w.

Forexcipients,see6.1.

3PHARMACEUTICALFORM

Cutaneouspowder

Anoff-white,absorbent,lightfreeflowingcutaneouspowderwithaslightodour.

4CLINICALPARTICULARS

4.1TherapeuticIndications

DriclorPowderisindicatedinthemanagementofintertrigo,hyperhidrosisandbromidrosisandinthepreventionof

Tineapedisandrelatedconditions.

4.2Posologyandmethodofadministration

TheaffectedareashouldbedriedasthoroughlyaspossiblebeforeapplyingDriclorPowder.DriclorPowdershouldbe

smoothedoverthesurfaceoftheskin,betweenjointsandfolds.

4.3Contraindications

Knownhypersensitivitytotheingredients.

4.4Specialwarningsandprecautionsforuse

Aswithallpowders,careshouldbetakentoavoidinhalation.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

None.

4.6Pregnancyandlactation

TherearenorestrictionsontheuseofDriclorPowderinpregnancyandlactation.

4.7Effectsonabilitytodriveandusemachines

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 07/12/2006 CRN 2030889 page number: 1

4.8Undesirableeffects

None.

4.9Overdose

Notapplicable.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

DriclorPowdercontainsaluminiumdihydroxyallantoinate.Aluminiumexertsabacteriostaticactionwhileallantoin

promotesphagocytosis.

Allantoinalsoactsasahydrogenbondbreaker,reducinghyperkeratinisationbyitsactionontheintercellularcement.

Theleucocyticstimulanteffectsofallantoincausedebridementofnecrotictissueandgenerationofnewtissue.

Theanti-irritantactionofaluminiumdihydroxyallantoinatemaybedependentontheneutralisationand/ordetoxication

ofirritants.Thistogetherwithitshealingandtissuenormalisingactionsmayberesponsibleforitsantipruriticeffects.

Theantibacterialactionpreventstheformationofbacterialmetabolitesortoxinswhichcauseodours.

Microporouscelluloseisanon-cakingwaterabsorbantpowderwhichexertsadryingactionbyabsorbingfluidfrom

theskinsurfacebycapillaryaction.

5.2Pharmacokineticproperties

Notapplicable.

5.3Preclinicalsafetydata

Notapplicable.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Chloroxylenol

MicrocrystallineCellulose

Talc

Perfume6A

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

3years.

6.4Specialprecautionsforstorage

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 07/12/2006 CRN 2030889 page number: 2

6.5Natureandcontentsofcontainer

Sifter-topplasticcontainersof50g.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

StiefelLaboratories(UK)Limited

HoltspurLane

WooburnGreen

HighWycombe

Buckinghamshire

HP100AU

8MARKETINGAUTHORISATIONNUMBER

PA144/12/2

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:01October1984

Dateoflastrenewal:01October2004

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 07/12/2006 CRN 2030889 page number: 3